- Home
- DBL vs VCRE Comparison
DBL vs VCRE Comparison
Compare DBL & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | DBL | VCRE |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.5M | 271.7M |
| IPO Year | 2011 | 2026 |
Fundamental Metrics
Financial Performance| Metric | DBL | VCRE |
|---|---|---|
| Price | $13.51 | $11.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $24.94 |
| AVG Volume (30 Days) | ★ 141.0K | 18.7K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $232.72 |
| Revenue Next Year | N/A | $340.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.94 | $7.88 |
| 52 Week High | $15.56 | $14.01 |
Technical Indicators
Market Signals| Indicator | DBL | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 62.41 |
| Support Level | $12.94 | $10.56 |
| Resistance Level | $14.40 | $11.88 |
| Average True Range (ATR) | 0.13 | 0.43 |
| MACD | -0.00 | 0.25 |
| Stochastic Oscillator | 9.08 | 98.31 |
Price Performance
Historical ComparisonAbout DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.